Mentabinol

**Mentabinol** is CanaQuest's proprietary, preclinical fixed-dose cannabinoid formulation containing tetrahydrocannabinol and L-theanine, designed to retain potential therapeutic effects of THC while reducing THC-associated neuropsychiatric and cognitive adverse effects. The program originated from sponsored research led by Dr. Steven Laviolette's team at Western University. CanaQuest reports animal-model findings of reduced THC-associated memory impairment, hyperactivity, depression-like and schizophrenia-related behaviors, and vulnerability-associated changes; these findings have not established clinical efficacy in humans. ([accessnewswire.com](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/canaquest-announces-award-of-european-cannabinoid-patent-785136))

Brand names

Mentabinol